• 1
    Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta–analysis. BMJ 2001;323:1015.
  • 2
    The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:417.
  • 3
    Franks S, Adams J, Mason H, Polson D. Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynaecol 1985;12:60532.
  • 4
    Nestler JE. Polycystic ovary syndrome: a disorder for the generalist. Fertil Steril 1998;70:81112.
  • 5
    Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:307882.
  • 6
    Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:400611.
  • 7
    NICE Fertility: assessment and treatment for people with fertility problems. Clinical Guideline. National Collaborating Centre for Women‘s and Children’s Health. Commissioned by the National Institute for Clinical Excellence. London: RCOG Press; 2004.
  • 8
    Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: DunaifA, GivensJR, HaseltineF, editors. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992. pp. 37784.
  • 9
    Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894901.
  • 10
    Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:18979.
  • 11
    Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997;350:11315.
  • 12
    Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries – a common finding in normal women. Lancet 1988;1:8702.
  • 13
    Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999;51:77986.
  • 14
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774800.
  • 15
    Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:E3929.
  • 16
    Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 2002;41(Suppl 1):S6583.
  • 17
    Franks S. Genetic and environmental origins of obesity relevant to reproduction. Reprod Biomed Online 2006;12:52631.
  • 18
    Azziz R, Kashar-Miller MD. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000;13(Suppl 5):13036.
  • 19
    Ehrmann DA. Genetic contributions to glucose intolerance in polycystic ovary syndrome. Reprod Biomed Online 2004;9:2834.
  • 20
    Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:4853.
  • 21
    Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:4297300.
  • 22
    Simpson JL. Molecular approach to common causes of female infertility. Best Pract Res Clin Obstet Gynaecol 2002;16:685702.
  • 23
    Amato P, Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:70718.
  • 24
    Heinonen S, Korhonen S, Helisalmi S, Koivunen R, Tapanainen JS, Laakso M. The 121Q allele of the plasma cell membrane glycoprotein 1 gene predisposes to polycystic ovary syndrome. Fertil Steril 2004;82:7435.
  • 25
    San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:26406.
  • 26
    Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002;78:12403.
  • 27
    Fox R. Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease. Gynecol Endocrinol 1999;13:3903.
  • 28
    Legro RS. Is there a male phenotype in polycystic ovary syndrome families? J Pediatr Endocrinol Metab 2000;13(Suppl 5):13079.
  • 29
    Duskova M, Cermakova I, Hill M, Vankova M, Samalikova P, Starka L. What may be the markers of the male equivalent of polycystic ovary syndrome? Physiol Res 2004;53:28794.
  • 30
    Starka L, Duskova M, Cermakova I, Vrbikova J, Hill M. Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome? Endocr Regul 2005;39:12731.
  • 31
    Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001;75:538.
  • 32
    Matilainen V, Laakso M, Hirsso P, Koskela P, Rajala U, Keinanen-Kiukaanniemi S. Hair loss, insulin resistance, and heredity in middle–aged women. A population-based study. J Cardiovasc Risk 2003;10:22731.
  • 33
    Ehrmann DA. Relation of functional ovarian hyperandrogenism to non-insulin dependent diabetes mellitus. Baillieres Clin Obstet Gynaecol 1997;11:33547.
  • 34
    Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:14154.
  • 35
    Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:1659.
  • 36
    Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:1416.
  • 37
    Sozen I, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Surv 2000;55:3218.
  • 38
    Maciel GA, Soares Junior JM, Alves da Motta EL, Abi Haidar M, De Lima GR, Baracat EC. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004;81:35560.
  • 39
    Maliqueo M, Sir-Petermann T, Salazar G, Perez-Bravo F, Recabarren SE, Wildt L. Resumption of ovarian function during lactational amenorrhoea in breastfeeding women with polycystic ovarian syndrome: metabolic aspects. Hum Reprod 2001;16:1598602.
  • 40
    Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; CD003053.
  • 41
    Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005;90:45938.
  • 42
    Balen AH, Dresner M, Scott EM, Drife JO. Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ 2006;332:4345.
  • 43
    Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004;89:275662.
  • 44
    Lord JM, Norman R. Obesity, polycystic ovary syndrome, infertility treatment: lifestyle modification is paramount. BMJ 2006;332:609.
  • 45
    HigginsJPT, GreenS, editors. Cochrane handbook for systematic reviews of interventions 4.2.6. In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd; 2006.
  • 46
    Hamilton-Fairley D, Kiddy D, Watson H, Paterson C, Franks S. Association of moderate obesity with a poor pregnancy outcome in women with polycystic ovary syndrome treated with low dose gonadotrophin. Br J Obstet Gynaecol 1992;99:12831.
  • 47
    Tulppala M, Stenman UH, Cacciatore B, Ylikorkala O. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. Br J Obstet Gynaecol 1993;100:34852.
  • 48
    Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993;8:95964.
  • 49
    Rai R, Backos M, Rushworth F, Regan L. Polycystic ovaries and recurrent miscarriage – a reappraisal. Hum Reprod 2000;15:61215.
  • 50
    Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:26069.
  • 51
    Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:5249.
  • 52
    Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004;10:32334.
  • 53
    Homburg R, Eshel A, Armar NA, Tucker M, Mason PW, Adams J, et al. One hundred pregnancies after treatment with pulsatile luteinising hormone releasing hormone to induce ovulation. BMJ 1989;298:80912.
  • 54
    Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, et al. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil Steril 1993;59:52731.
  • 55
    Tarlatzis BC, Grimbizis G, Pournaropoulos F, Bontis J, Lagos S, Spanos E, et al. The prognostic value of basal luteinizing hormone: follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques. Hum Reprod 1995;10:25459.
  • 56
    Hasegawa I, Tanaka K, Sanada H, Imai T, Fujimori R. Studies on the cytogenetic and endocrinologic background of spontaneous abortion. Fertil Steril 1996;65:524.
  • 57
    Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988;297:10246.
  • 58
    Doldi N, Gessi A, Destefani A, Calzi F, Ferrari A. Polycystic ovary syndrome: anomalies in progesterone production. Hum Reprod 1998;13:2903.
  • 59
    Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006;55:34552.
  • 60
    Palomba S, Orio F , Falbo A, Russo T, Tolino A, Zullo F. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. Fertil Steril 2005;84:7615.
  • 61
    Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:158995.
  • 62
    Jakubowicz DJ, Essah PA, Seppala M, Jakubowicz S, Baillargeon JP, Koistinen R, et al. Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004;89:8339.
  • 63
    Bayraktar F, Dereli D, Ozgen AG, Yilmaz C. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 2004;51:6018.
  • 64
    Ibanez L, Jaramillo AM, Ferrer A, De Zegher F. High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 2005;20:245762.
  • 65
    Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:60617.
  • 66
    Taponen S, Martikainen H, Jarvelin MR, Sovio U, Laitinen J, Pouta A, et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab 2004;89:211418.
  • 67
    Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:1237.
  • 68
    Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21:142631.
  • 69
    Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004;150:52532.
  • 70
    Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:55926.
  • 71
    Gonzalez F, Rote NS, Minium J, Kirwan JP. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome. J Endocrinol 2006;188:5219.
  • 72
    Orio F , Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:25.
  • 73
    Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003;46:62533.
  • 74
    Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 2004;60:5607.
  • 75
    Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90:601421.
  • 76
    Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001;75:4652.
  • 77
    Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 2006;85:10029.
  • 78
    Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 2003;18:7217.
  • 79
    Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:464954.
  • 80
    Ron-El R, Raziel A, Schachter M, Strassburger D, Kasterstein E, Friedler S. Induction of ovulation after gnRH antagonists. Hum Reprod Update 2000;6:31821.
  • 81
    Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:132330.
  • 82
    Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006;86:65863.
  • 83
    Engmann L, Maconochie N, Sladkevicius P, Bekir J, Campbell S, Tan SL. The outcome of in-vitro fertilization treatment in women with sonographic evidence of polycystic ovarian morphology. Hum Reprod 1999;14:16771.
  • 84
    Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod 2002;17:32203.
  • 85
    Wang JX, Davies MJ, Norman RJ. Obesity increases the risk of spontaneous abortion during infertility treatment. Obes Res 2002;10:5514.
  • 86
    Bellver J, Rossal LP, Bosch E, Zuniga A, Corona JT, Melendez F, et al. Obesity and the risk of spontaneous abortion after oocyte donation. Fertil Steril 2003;79:113640.
  • 87
    Nardo LG, Rai R, Backos M, El-Gaddal S, Regan L. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2002;77:34852.
  • 88
    Heard MJ, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002;77:66973.
  • 89
    Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002;17:285864.
  • 90
    Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 2004;21:82936.
  • 91
    Liddell HS, Sowden K, Farquhar CM. Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust N Z J Obstet Gynaecol 1997;37:4026.
  • 92
    McClure N, McDonald J, Kovacs GT, Healy DL, McCloud PI, McQuinn B, et al. Age and follicular phase estradiol are better predictors of pregnancy outcome than luteinizing hormone in menotropin ovulation induction for anovulatory polycystic ovarian syndrome. Fertil Steril 1993;59:72933.
  • 93
    Bahceci M, Ulug U. Does underlying infertility aetiology impact on first trimester miscarriage rate following ICSI? A preliminary report from 1244 singleton gestations. Hum Reprod 2005;20:71721.
  • 94
    Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003;52:162732.
  • 95
    Ciampelli M, Lanzone A, Caruso A. Insulin in obstetrics: a main parameter in the management of pregnancy. Hum Reprod Update 1998;4:90414.
  • 96
    Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 2004;19:51021.
  • 97
    Paradisi G, Fulghesu AM, Ferrazzani S, Moretti S, Proto C, Soranna L, et al. Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy. Hum Reprod 1998;13:5426.
  • 98
    Homburg R. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab 2006;20:28192.
  • 99
    Fowler DJ, Nicolaides KH, Miell JP. Insulin-like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Hum Reprod Update 2000;6:495504.
  • 100
    Jensen RB, Chellakooty M, Vielwerth S, Vaag A, Larsen T, Greisen G, et al. Intrauterine growth retardation and consequences for endocrine and cardiovascular diseases in adult life: does insulin-like growth factor-I play a role? Horm Res 2003;60(Suppl 3):13648.
  • 101
    Diamant YZ, Rimon E, Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1982;14:199204.
  • 102
    Gjonnaess H. The course and outcome of pregnancy after ovarian electrocautery in women with polycystic ovarian syndrome: the influence of body-weight. Br J Obstet Gynaecol 1989;96:71419.
  • 103
    De Vries MJ, Dekker GA, Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study. Eur J Obstet Gynecol Reprod Biol 1998;76:915.
  • 104
    Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 1999;94:1947.
  • 105
    Fridstrom M, Nisell H, Sjoblom P, Hillensjo T. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? Hypertens Pregnancy 1999;18:7380.
  • 106
    Kashyap S, Claman P. Polycystic ovary disease and the risk of pregnancy-induced hypertension. J Reprod Med 2000;45:9914.
  • 107
    Mikola M, Hiilesmaa V, Halttunen M, Suhonen L, Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001;16:2269.
  • 108
    Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Perez-Bravo F. Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002;45:95964.
  • 109
    Bjercke S, Dale PO, Tanbo T, Storeng R, Ertzeid G, Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002;54:948.
  • 110
    Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 2003;18:143841.
  • 111
    Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004;19:173440.
  • 112
    Weerakiet S, Srisombut C, Rojanasakul A, Panburana P, Thakkinstian A, Herabutya Y. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome. Gynecol Endocrinol 2004;19:13440.
  • 113
    Al-Ojaimi EH. Pregnancy outcomes after laparoscopic ovarian drilling in women with polycystic ovarian syndrome. Saudi Med J 2006;27:51925.
  • 114
    Nelson-Piercy C, Gale EA. Do we know how to screen for gestational diabetes? Current practice in one regional health authority. Diabet Med 1994;11:4938.
  • 115
    Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med 2002;19:3518.
  • 116
    Grover J, Beall MH, Ross MG. Intrapartum screen for diabetes in patients without prenatal care: use of labor admission serum glucose. J Matern Fetal Med 2000;9:21618.
  • 117
    Mathai M, Thomas TJ, Karuvila S, Jairaj P. Random plasma glucose and the glucose challenge test in pregnancy. Natl Med J India 1994;7:1602.
  • 118
    Ostlund I, Hanson U. Repeated random blood glucose measurements as universal screening test for gestational diabetes mellitus. Acta Obstet Gynecol Scand 2004;83:4651.
  • 119
    Watson WJ. Screening for glucosuria in pregnancy. South Med J 1990;83:1568.
  • 120
    McElduff A, Goldring J, Gordon P, Wyndham L. A direct comparison of the measurement of a random plasma glucose and a post-50 g glucose load glucose, in the detection of gestational diabetes. Aust N Z J Obstet Gynaecol 1994;34:2830.
  • 121
    Wu LF, Liu DY, Huang XH, Zu XS, Yang M, Liu WJ, et al. [Multicenter study on screen method for gestational diabetes]. Zhonghua Fu Chan Ke Za Zhi 2003;38:1325.
  • 122
    Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:67383.
  • 123
    Kashyap S, Claman P. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001;16:1537.
  • 124
    Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF. Transfer of metformin into human milk. Diabetologia 2002;45:150914.
  • 125
    Briggs GG, Ambrose PJ, Nageotte MP, Padilla G, Wan S. Excretion of metformin into breast milk and the effect on nursing infants. Obstet Gynecol 2005;105:143741.
  • 126
    Gardiner SJ, Begg EJ, Kirkpatrick CMJ, Buckham RB. Metformin therapy and diabetes in pregnancy. Med J Aust 2004;181:1745.
  • 127
    Glueck CJ, Salehi M, Sieve L, Wang P. Growth, motor social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr 2006;148:62832.
  • 128
    Checa MA, Requena A, Salvador C, Tur R, Callejo J, Espinos JJ, et al. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 2005;11:37590.
  • 129
    Simmons D, Walters BN, Rowan JA, McIntyre HD. Metformin therapy and diabetes in pregnancy. Med J Aust 2004;180:4624.
  • 130
    Barker DJP. The developmental origins of adult disease. J Am Coll Nutr 2004;23(Suppl 6):588S–95S.
  • 131
    Hattersley AT, Tooke JE. The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet 1999;353:178992.
  • 132
    Muth S, Norman J, Sattar N, Fleming R. Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements? Hum Reprod 2004;19:271820.
  • 133
    Brown FM, Wyckoff J, Rowan JA, Jovanovic L, Sacks DA, Briggs GG. Metformin in pregnancy: its time has not yet come. Diabetes Care 2006;29:4856.